Does Ozempic protect against COVID and infections?

Yes, at least in one high risk group. In this analysis of the FLOW trial, adults with type 2 diabetes and chronic kidney disease who took once weekly semaglutide 1.0 mg had about a 21% lower risk of a serious infection, a hospital stay for infection, or death from any cause than adults who took placebo (hazard ratio 0.79).

Semaglutide is the drug sold as Ozempic at this dose and as Wegovy at a higher one. It is prescribed for blood sugar and weight, and the FLOW trial had already shown it protects the kidneys and the heart in people with type 2 diabetes and chronic kidney disease. This new report was planned in advance as part of that same trial, and it asked a different question: did the people on semaglutide also get fewer bad infections, including COVID-19?

The answer was yes, and the size of the effect is not small. The confidence range around that 21% figure runs from 11% to 31% lower risk, so the true benefit is very likely somewhere in that band. The odds that a result this strong came from chance alone were about 2 in 10,000.

What the data show

The clearest numbers are the raw event rates. Serious infections of any kind happened in 17.9% of the semaglutide group and 21.3% of the placebo group. That is 3.4 fewer people out of every 100, or 34 fewer per 1,000, which works out to about 29 people treated to prevent one serious infection. There was about a 7 in 1,000 chance of seeing a gap that large by luck.

Hospital admissions for infection followed the same pattern, 17.5% with semaglutide versus 20.4% with placebo, or about 29 fewer hospitalizations per 1,000 people. COVID-19 specifically also moved. Serious COVID-19 events occurred in 6.7% of the semaglutide group and 8.8% of the placebo group, roughly 21 fewer serious COVID cases per 1,000 people, and COVID-19 of any severity showed up in 20.3% versus 22.9%.

Dr. Kumar’s Take

A 21% reduction in a composite that includes death from any cause is a serious signal, and it came out of a randomized trial rather than a database study, which means the comparison is fair. That matters. Most of what gets written about GLP-1 drugs and infection risk comes from observational data, where healthier people tend to be the ones filling the prescriptions.

The mechanism is the open question. Better blood sugar control alone could explain much of this, since high glucose impairs how white blood cells work. Weight loss, less inflammation, and healthier kidneys could each contribute too. This analysis cannot separate those threads, and the subgroup pattern hints that glucose is doing a lot of the work.

I would not read this as a reason to take semaglutide for infection protection. It is a reason to stop thinking of the drug as a blood sugar and weight medication and start thinking of it as something that changes the overall risk profile of a sick population.

Who benefits most

The benefit was far from evenly spread. In people whose hemoglobin A1c was above 8%, meaning poorly controlled blood sugar, semaglutide cut the risk by about 37% (hazard ratio 0.63, very likely between 24% and 48% lower). In people at or below 8%, the reduction was about 7% and the range crossed the point of no effect, so no real benefit was shown there. The chance that this split was random was about 3 in 1,000.

The same thing happened with kidney damage. Among people spilling the most protein in their urine, an albumin to creatinine ratio of 2000 mg/g or higher, the risk dropped about 47% (hazard ratio 0.53, very likely between 28% and 61% lower). Among those below 100 mg/g, no clear benefit appeared. The sicker the kidney, the bigger the payoff.

How strong is the evidence?

This came from a randomized, placebo controlled trial, which is the strongest design available, and the analysis was pre-specified rather than dug up after the fact. Both points count in its favor.

The limits are real, though. Everyone in FLOW had both type 2 diabetes and chronic kidney disease, so these numbers say nothing about a healthy person taking semaglutide for weight loss. Infections were captured as reported adverse events during a kidney trial, not hunted for with a dedicated infection protocol. And the main outcome bundles death from any cause together with infection, so part of that 21% reflects the drug’s already known survival benefit rather than infection protection alone.

Practical takeaways

If you have type 2 diabetes and chronic kidney disease and are already on semaglutide, this is one more reason to stay consistent with it rather than skipping doses.
Poorly controlled blood sugar, an A1c above 8%, appears to be where the infection benefit is concentrated, so getting that number down deserves attention no matter which drug does it.
Do not treat this as a substitute for vaccination or ordinary infection precautions, since the trial compared semaglutide against placebo and not against any preventive measure.
Ask your doctor about urine albumin testing if you have diabetes, because the amount of protein in your urine tracked closely with how much benefit people got.

Frequently asked questions

Does this mean semaglutide works like an antiviral against COVID-19?

No. Nothing in this analysis shows semaglutide attacking the virus. The trial tracked how many people ended up with serious COVID-19 events, and fewer did in the semaglutide group, but that is a difference in outcomes and not evidence of antiviral action. A more likely explanation is that the drug improved the conditions that make COVID-19 dangerous in the first place, such as high blood sugar, excess weight, and failing kidneys. Distinguishing between the two would take a completely different kind of study.

Would a lower dose of semaglutide give the same protection?

The trial only tested one dose, 1.0 mg injected once a week, so there is no evidence here about lower or higher doses. Semaglutide is prescribed at several strengths depending on whether it is being used for blood sugar or for weight, and the results in this paper apply only to the dose that was studied. Anyone hoping to extend these findings to a different strength is guessing. The dose question is worth raising with your own physician rather than settling from a trial that did not test it.

If I do not have kidney disease, does any of this apply to me?

Not directly. Every participant in FLOW had both type 2 diabetes and chronic kidney disease, and the subgroup results actually argue against generalizing. People with the least kidney damage and the best blood sugar control showed no clear benefit at all. That pattern suggests the protection depends on having something meaningful to fix. A healthy adult taking semaglutide for weight would need a separate trial to know whether infections change at all.

The bottom line

In adults with type 2 diabetes and chronic kidney disease, once weekly semaglutide lowered the combined risk of serious infection, hospitalization for infection, or death by about 21%, with fewer serious COVID-19 events and fewer infection hospitalizations along the way. The benefit concentrated in the sickest patients, those with an A1c above 8% or heavy protein loss in the urine, where the risk fell by 37% and 47% respectively. This does not turn a diabetes drug into an infection shield, but it does widen the list of things semaglutide appears to change in people who are already at high risk.

Read the full study